Investment In A QuÃ©bec Public-private Partnership To Support The Use Of Personalized Medicine Solutions In The Treatment Of Cancer Patients
MONTREAL, Feb. 15, 2013 /PRNewswire/ - The Government of Québec announced today a $10 million investment in the Personalized Medicine Partnership for Cancer (PMPC). This public-private partnership will be focused on establishing an integrated approach for the development and implementation of clinical biomarkers and other personalized healthcare solutions to improve the outcome and cost-efficiency of healthcare services provided to cancer patients in the province of Québec and abroad. The investment, to be disbursed over a 4 year period, will be supplemented with $11.1 million of funding from the private sector partners, for a total project value of $21.1 million.
The PMPC will be under the leadership of Caprion Proteome Inc., a Montreal-based biotech company specializing in the discovery and development of protein-based diagnostic biomarkers. The other partners will include the Québec Clinical Research Organization in Cancer (Q-CROC), a multidisciplinary network of clinicians, academic scientists and other members of the medical community involved in clinical and translational cancer research, as well as private partners Oncozyme Pharma Inc., Pfizer Canada Inc., Sanofi Canada Inc. and TELUS Health.
As part of the projects supported through this partnership, state-of-the-art genomic, proteomic, bioinformatic and information technology platforms will be implemented to develop and deploy novel biomarkers and targeted therapeutic strategies in the healthcare system for the treatment of lung, colon and breast cancers: " The sequence of our genome or the profile of the proteins in our blood can be used to accurately predict disease progression or treatment outcome. Our partnership will integrate advanced technology platforms with clinical research to accelerate the development and clinical deployment of novel personalized healthcare solutions. Caprion has pioneered such strategies for years, and with our partners, we are committed to delivering tangible results to provide more targeted diagnosis and treatments for cancer," said Martin LeBlanc, President and Chief Executive Officer of Caprion Proteome.
Personalized medicine has been coined to describe the use of specific patient information gathered from tumour, blood or other specimens to characterize disease subtype and select the optimal treatment. " The rapid progress in clinical research enables us to decipher the underpinnings of cancer and to develop specific diagnostic tools and targeted drugs to treat specific subtypes of common cancers such as lung, colon or breast. It is critical that these new tools and medicines be deployed for the benefit of patients across Québec," said Gerald Batist, Professor of Oncology at McGill University and Co-director of the Q-CROC and Director of the Segal Cancer Center at the Jewish General Hospital. "While technology has been progressing rapidly, it will be critical to prepare our healthcare system to integrate the wealth of new molecular information and educate professionals in the practice of personalized medicine," he added.The PMPC project stemmed from the Stratégie québécoise de la recherche et de l'innovation (SQRI) that was created by the Government of Québec to advance knowledge and accelerate the deployment of innovative personalized medicine solutions to the bedside. The partnership, in collaboration with the Ministère de la santé et des services sociaux (MSSS), was also built to strengthen the cooperation between the private and the public research sectors including academic healthcare institutions and universities.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV